![Michael Anstey](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Michael Anstey
Chief Investment Officer bei
Congenica Ltd.
Profil
Michael Anstey is the founder of Proteorex Therapeutics, Inc., founded in 2014.
Current jobs include Director at Buckman Laboratories SARL, Director & Investment Director at Congenica Ltd. since 2019, Director at Start Codon Ltd. since 2019, Director at Epitopea Ltd. since 2021, and Partner at Cambridge Innovation Capital Ltd since 2017.
Former jobs include Independent Director at Bicycle Therapeutics Plc from 2017 to 2020, Director at STORM Therapeutics Ltd., Director at Sense Biodetection Ltd. from 2019 to 2023, Principal-Healthcare Practice Area at The Boston Consulting Group, Inc. from 2010 to 2017, Investment Analyst at Oxford Capital Partners LLP from 2008 to 2009, and Board Member at Polyprox Therapeutics Ltd. Education includes a doctorate from the University of Oxford conferred in 2007 and an undergraduate degree from Queen's University conferred in 2003.
Aktive Positionen von Michael Anstey
| Unternehmen | Position | Beginn |
|---|---|---|
Buckman Laboratories SARL
 Buckman Laboratories SARL Chemicals: Major DiversifiedProcess Industries Whole sells chemicals | Direktor/Vorstandsmitglied | 08.02.2010 |
Cambridge Innovation Capital Ltd
 Cambridge Innovation Capital Ltd Investment ManagersFinance Cambridge Innovation Capital seeks investment opportunities in companies located in the United Kingdom. The firm focuses on technology and life science companies. It participates in seed, early and late stage capital transactions. The firm makes co-investments. | Private Equity Investor | 01.01.2017 |
Congenica Ltd.
 Congenica Ltd. Packaged SoftwareTechnology Services Operates as a digital health company that enables analysis of genomic data | Chief Investment Officer | 01.01.2019 |
Start Codon Ltd.
 Start Codon Ltd. Investment ManagersFinance Start Condon invest in private companies located in the United Kingdom. The firm focuses on the healthcare sector. It participates in seed, early and later stage capital requirements with an investment size of GBP 250,000. | Direktor/Vorstandsmitglied | 01.04.2019 |
Epitopea Ltd.
 Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and experimental development on biotechnology | Direktor/Vorstandsmitglied | 01.11.2021 |
Ehemalige bekannte Positionen von Michael Anstey
| Unternehmen | Position | Ende |
|---|---|---|
Sense Biodetection Ltd.
 Sense Biodetection Ltd. Medical/Nursing ServicesHealth Services Engages in molecular diagnostic testing | Direktor/Vorstandsmitglied | 01.01.2023 |
| BICYCLE THERAPEUTICS PLC | Direktor/Vorstandsmitglied | 30.06.2020 |
Proteorex Therapeutics, Inc.
 Proteorex Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Gründer | 01.12.2018 |
The Boston Consulting Group, Inc.
 The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Corporate Officer/Principal | 01.01.2017 |
| ░░░░░░ ░░░░░░░ ░░░░░░░░ ░░░ | ░░░░░░░░░░░░░░░░░░░░░░ | ░░░░░░░░░░ |
Ausbildung von Michael Anstey
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
96
Beziehungen ersten Grades
14
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 14 |
|---|---|
University of Oxford
 University of Oxford Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
The Boston Consulting Group, Inc.
The Boston Consulting Group, Inc. Miscellaneous Commercial ServicesCommercial Services Provides management consulting services | Commercial Services |
Queen's University
 Queen's University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Oxford Capital Partners LLP
 Oxford Capital Partners LLP Investment ManagersFinance Oxford Capital Partners invests in companies located in the United Kingdom. The firm focuses on a broad range of sectors and industries. It provides financing for seed and early stage capital transactions. The firm makes co-investments and takes a seat on the board of directors. The firm makes follow-on investments. | Finance |
Bicycle Therapeutics Plc
 Bicycle Therapeutics Plc Pharmaceuticals: MajorHealth Technology Operates as a biopharmaceutical company that develops molecules and oncology medicines | Health Technology |
Buckman Laboratories SARL
Buckman Laboratories SARL Chemicals: Major DiversifiedProcess Industries Whole sells chemicals | Process Industries |
Congenica Ltd.
Congenica Ltd. Packaged SoftwareTechnology Services Operates as a digital health company that enables analysis of genomic data | Technology Services |
Cambridge Innovation Capital Ltd
Cambridge Innovation Capital Ltd Investment ManagersFinance Cambridge Innovation Capital seeks investment opportunities in companies located in the United Kingdom. The firm focuses on technology and life science companies. It participates in seed, early and late stage capital transactions. The firm makes co-investments. | Finance |
STORM Therapeutics Ltd.
 STORM Therapeutics Ltd. BiotechnologyHealth Technology Operates as a clinical-stage biotechnology company that develops molecule drugs through RNA biology for the treatment of cancer, inflammation, viruses and CNS diseases | Health Technology |
Sense Biodetection Ltd.
Sense Biodetection Ltd. Medical/Nursing ServicesHealth Services Engages in molecular diagnostic testing | Health Services |
Proteorex Therapeutics, Inc.
Proteorex Therapeutics, Inc. BiotechnologyHealth Technology Develops novel therapeutics | Health Technology |
Start Codon Ltd.
Start Codon Ltd. Investment ManagersFinance Start Condon invest in private companies located in the United Kingdom. The firm focuses on the healthcare sector. It participates in seed, early and later stage capital requirements with an investment size of GBP 250,000. | Finance |
Polyprox Therapeutics Ltd.
 Polyprox Therapeutics Ltd. BiotechnologyHealth Technology Operates as biotechnology company which engages in research and development of drugs to treat cancer and neurodegenerative diseases | Health Technology |
Epitopea Ltd.
Epitopea Ltd. Miscellaneous Commercial ServicesCommercial Services Engages in research and experimental development on biotechnology | Commercial Services |
Wählen Sie MarketScreener 
